October 27, 2020 -- The Global Coalition for Adaptive Research (GCAR) said that the first patient has been enrolled in an adaptive multicenter clinical trial to test interventions for hospitalized COVID-19 patients.
The patient was enrolled in the Randomized Embedded Multifactorial Adaptive Platform (REMAP)-COVID, a substudy of the trial REMAP-Community-Acquired Pneumonia (CAP). In the multicenter, randomized study, Amgen's apremilast drug and Eisai's investigational eritoran toll-like receptor 4 (TLR4) antagonist will be evaluated as potential therapeutic agents for COVID-19.
The trial is being conducted at the University of Pittsburgh Medical Center health system, along with over 20 other U.S. hospitals. Global sites will also be added to the trial, according to GCAR, Amgen, and Eisai.
Copyright © 2020 scienceboard.net